1. Home
  2. Research Projects

Research Projects

A multidisciplinary team of basic and clinical investigators directs all projects within the MSKCC-Cornell Center for Translation of Cancer Nanomedicines (MC2TCN). These teams participate fully in the broad research endeavor, striving to use insights from each project to develop and further the aims of the other projects. The “team science” approach extends beyond the boundaries of MC2TCN to include vital collaborations with other academic institutions, CCNEs, federal agencies, and industry.

The strengths that will enable our Center to initiate projects like the ones below include: outstanding researchers from diverse fields of expertise, experienced leadership, collaborations with members of the NCI Alliance for Nanotechnology, and supplemental financial support from key grants and institutional funds.

Highly-Integrated Ultrasmall and Bright Fluorescent Silica Particle Architectures

A basic research effort led by Ulrich Wiesner on the synthesis and exploration of novel classes of < 10 nm C dots synthesized in water for use as cancer-targeted diagnostic and therapeutic probes.

Real-time Intraoperative Imaging of Cancer Biomarkers and Peripheral Nerves

A translational research effort led by Michelle Bradbury and co-lead Snehal Patel, Associate Professor of Surgery at MSKCC on the optimization of new generation C dots for earlier and more reliable detection of multiple targets on melanoma-bearing lymph nodes and / or adjacent nerves, using an FDA-approved handheld intraoperative fluorescence camera.

Targeted Ultrasmall Silica Nanoparticles for Alpha- and Beta-Emitting Radiotherapy

The primary objectives of translational research Project 3 are to (1) target radiolabeled C dots to melanoma to deliver highly localized radiation doses and (2) deliver and release SMIs from nanoparticle-drug conjugates (NDCs) to malignant brain tumors.

Targeted Ultrasmall Silica Nanoparticles for Delivery of Small Molecule Inhibitors

The primary objectives of translational research Project 3 are to (1) target radiolabeled C dots to melanoma to deliver highly localized radiation doses and (2) deliver and release SMIs from nanoparticle-drug conjugates (NDCs) to malignant brain tumors.